TOP TIERMARKET NEWSWIRE

News & sentiment

COYA THERAPEUTICS IN (COYA) — News & AI sentiment

COYA THERAPEUTICS IN (COYA) news roundup. 7 stories aggregated over the last 30 days. Average 30-day sentiment is 54.9/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

0

30d stories

7

avg sentiment 54.9/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

COYA news in the last 24 hours, 7 days, 30 days and 90 days

How much COYA coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	COYA stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	0	—	no coverage
Last 30 days	7	54.9/100	COYA headlines →
Last 90 days	22	56.3/100	COYA headlines →

Latest stories on COYA

Coya Therapeutics announces poster presentation on NfL biomarker methodology

The Fly56 · neutralproduct/pr

Oct 28

Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting

StockTitan56 · neutralproduct/pr

Oct 28

Coya Therapeutics, Inc. (COYA) files 8-K

SEC 8-K50 · neutralgeneral

Oct 14

Coya Therapeutics to initiate OLE of Phase 2/3 ALSTARS trial of COYA 302

The Fly58 · neutralproduct/pr

Oct 14

Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS

StockTitan58 · neutralproduct/pr

Oct 14

COYA Joins Chardan Healthcare Conference Panel on ALS, Alzheimer’s, and Parkinson’s October 13, 2026

MarketChameleon53 · neutralproduct/pr

Oct 13

Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference

StockTitan53 · neutralproduct/pr

Oct 13

Coya Therapeutics stock reiterated at Buy by H.C. Wainwright on trial enrollment

Investing.com Analyst Ratings61 · neutralanalyst

Oct 6

Coya Therapeutics, Inc. (COYA) files 8-K

SEC 8-K50 · neutralgeneral

Oct 5

Coya announces full enrollment in Phase 2/3 ALSTARs trial of COYA 302

The Fly67 · bullishproduct/pr

Oct 5

Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

StockTitan63 · neutralproduct/pr

Oct 5

Coya Therapeutics stock maintained at Buy by H.C. Wainwright

Investing.com Analyst Ratings61 · neutralanalyst

Sep 25

Coya Therapeutics, Inc. (COYA) files 8-K

SEC 8-K50 · neutralgeneral

Sep 15

Coya Therapeutics announces 100th patient enrolled in Phase 2/3 ALSTARS trial

The Fly63 · neutralproduct/pr

Sep 15

Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

StockTitan67 · bullishproduct/pr

Sep 15

Coya announces publication of preclinical study on effects of COYA 303

The Fly59 · neutralproduct/pr

Sep 8

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation

StockTitan63 · neutralproduct/pr

Sep 8

H.C. Wainwright reiterates Coya Therapeutics stock rating at buy

Investing.com Analyst Ratings61 · neutralanalyst

Aug 24

Coya Therapeutics Reports Q2 Eps 28c Consensus 36c

The Fly34 · bearishearnings

Aug 11

Coya Therapeutics GAAP EPS of -$0.28 beats by $0.07, revenue of $0.24M beats by $0.14M

Seeking Alpha56 · neutralearnings

Aug 11

Coya Therapeutics, Inc. (COYA) files 8-K

SEC 8-K50 · neutralgeneral

Aug 11

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

StockTitan50 · neutralgeneral

Aug 11

8-K/A - Coya Therapeutics, Inc. (COYA) files 8-K

SEC 8-K50 · neutralgeneral

Aug 7

Coya Therapeutics, Inc. (COYA) files 8-K

SEC 8-K50 · neutralgeneral

Jun 25

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting | COYA Stock News

StockTitan56 · neutralproduct/pr

Jun 18

Open COYA in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →